Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Abstract Background Despite promising outcomes of treatment with anti-programmed cell death (PD)-1/PD-ligand (L)1 agents in combination with platinum-doublet chemotherapy (PDC) in the first-line setting, a significant unmet medical need remains in patients with PD-L1-unselected non-small cell lung c...

Full description

Saved in:
Bibliographic Details
Main Authors: Armando Santoro, Garrido Pilar, Daniel S.W. Tan, Jon Zugazagoitia, Frances A. Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R. Overbeck, Enriqueta Felip, Can Cai, Simantini Eddy, Tracey McCulloch, Eric S. Schaefer
Format: Article
Language:English
Published: BMC 2024-10-01
Series:BMC Cancer
Subjects:
Canakinumab
NSCLC
PD-L1
Platinum-doublet chemotherapy
Spartalizumab
Online Access:https://doi.org/10.1186/s12885-024-12841-2
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items